Epitope of optimized humanized monoclonal antibodies against activated protein C and uses thereof

US11077187B2 · kind B2 · utility

Assignee

• Oklahoma Medical Research Foundation · US

Inventors

• Xiao-Yan Zhao · Union City, US
• Andreas Wilmen · Neunburg vorm Wald, DE
• Christoph Freiberg · Wuppertal, DE
• Lars Linden · Mülheim an der Ruhr, DE
• Ji-Yun Kim · Changwon-si, KR
• Subramanian Yegneswaran · Pleasanton, US
• Karin Regnstrom · San Francisco, US
• Ursula Egner · Berlin, DE
• Xinquan Wang · Zhejiang, CN

Key dates

• Filing date: Nov 15, 2016
• Grant date: Aug 3, 2021
• Expiry date: Mar 3, 2037

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2317/94
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Provided are optimized humanized antibodies that selectively bind to and inhibit activated protein C without binding to or inhibiting unactivated protein C. In particular, the antibodies bind to particular epitopes outside the catalytic triad of the active site of human activated protein C. Methods of treatment employing these antibodies are described herein.